العربيةStart a conversationContact
Insights

Valuation Brief · Healthcare & Life Sciences · 8 November 2026

Abu Dhabi's Unified Procurement Program moved in-scope drug revenue to a net basis. Margins went up, reported revenue went down, and EBITDA in dirhams rose far less, or not at all. A buyer comparing years, or comparing peers, is comparing two different income statements.

Since DoH began activating the Unified Procurement Program for drugs from 15 April 2025, Abu Dhabi providers bill Thiqa, Basic and government-mandate payers a markup on in-scope outpatient and day-case medicines instead of the drug itself. Listed operators now report that revenue on a net basis: Burjeel's H1 2026 revenue grew 4.4% reported and 9.1% excluding UPP, and PureHealth's UAE Care margin rose to 20.0% from 17.7% on revenue that fell 9.2%. A higher margin on a smaller base is not more profit, and the dirham figure can fall. Before pricing an Abu Dhabi provider, restate its history and its comparables on one basis.

The 30-second read

What a board member needs before the next meeting on this.

  1. The hospital now bills a markup, not a medicine. For UPP-flagged drugs under Thiqa, Basic and the government's funded mandates, DoH reimburses the provider's markup and a single distributor replenishes the stock. Activation was gradual from 15 April 2025 under Circular 29/2025.
  2. Scope follows payer and service mix. Addendum 02 excludes inpatient and long-term care drugs, applies to day cases only above AED 1,000 of in-scope drugs at public price, and does not apply to Enhanced policies.
  3. The operators have published the gap. Burjeel's H1 2026 revenue grew 4.4% reported and 9.1% excluding UPP. PureHealth's UAE Care margin rose to 20.0% from 17.7% on reported revenue down 9.2%, partly on a lower reported revenue base.
  4. Compare dirhams before percentages. Against PureHealth's normalised UAE revenue the margin is about 17.2% on our arithmetic. Burjeel reports Burjeel Medical City's Q1 2026 EBITDA at AED 52 million, AED 61 million normalised.
Applies to Buyers, sellers, lenders and boards pricing an Abu Dhabi hospital, clinic group or pharmacy with Thiqa, Basic or government-mandate patients, and anyone using Abu Dhabi listed operators as valuation comparables

Abu Dhabi's government health programmes no longer pay hospitals the price of in-scope outpatient medicines. Under the Unified Procurement Program, DoH buys in-scope drugs centrally, a distributor replenishes the provider's shelf, and the provider is reimbursed for the medicine replenished plus a markup (DoH Circular 29/2025). Listed operators now report that revenue net, and their Abu Dhabi margins have risen. A buyer who reads the higher margin as better operations, or sets a post-programme peer margin against a target's pre-programme accounts, will price the wrong number.

How the basis changed12 Feb 2025Circular 14/2025:markup-only billing15 Apr 2025Gradual activationunder Circular 29/2025Aug 2025Burjeel datesits UPP effectNowPre-UPP historystill reported gross
01

The hospital now bills a markup, not a medicine

DoH Circular 14/2025, dated 12 February 2025, set reimbursement for UPP-flagged drugs at the markup amount only, waived existing contractual discounts between Daman and pharmacies on those drugs, and applied the programme to all encounters except inpatient overnight stays (DoH Circular 14/2025). Circular 29/2025, dated 4 March 2025, made activation gradual from 15 April 2025 (DoH Circular 29/2025).

Circular 27/2025 added a unit markup, a package markup and a UPP effective date to each line of the Abu Dhabi Drug Coding List (DoH Circular 27/2025). Circular 81/2025, effective 1 June 2025, has the distributor replenish provider stock and DoH fund the purchases through government programme accounts (DoH Circular 81/2025). On our reading, for an in-scope drug the provider keeps the markup and no longer carries the drug's price in revenue or its cost in inventory consumed.

02

Scope decides how much of a hospital moves

Addendum 02 to the DoH Claims and Adjudication Rules excludes drugs used in inpatient and long-term care encounters, applies to day cases only where in-scope drugs reach AED 1,000 in cumulative cost at public price, and does not apply to Enhanced policies (DoH Addendum 02). The payers in scope are Thiqa, the Basic policy and the funded mandates of the Abu Dhabi government (DoH Circular 14/2025).

Exposure therefore follows payer and service mix: an inpatient-led hospital serving Enhanced members moves far less. Burjeel's FY2025 MD&A says growth at Burjeel Medical City moderated in the fourth quarter on higher UPP exposure, with Thiqa patients more than half its patient base and the largest share of the group's oncology activity (Burjeel FY2025 MD&A).

Working a decision this brief touches? Start with a principal. Start a conversation

03

Both Listed operators have published the gap

Burjeel reported H1 2026 revenue up 4.4% to AED 2,794 million, and 9.1% excluding the impact of UPP, stating that certain medicines are procured directly by the authorities, with the group earning a fixed service fee instead of full revenue recognition (Burjeel H1 2026 MD&A).

PureHealth reported UAE Care revenue of AED 8.7 billion for the first nine months of 2026, down 9.2%, citing UPP revenue recognition, internal revenue eliminations and lower first-quarter activity; on its normalised basis revenue rose 6% to AED 10.1 billion. UAE Care EBITDA rose 3% to AED 1.74 billion and the margin moved to 20.0% from 17.7%, which PureHealth attributes in part to the impact of a lower reported revenue base (PureHealth 9M 2026 results).

04

A higher margin on a smaller base is not more profit

Set PureHealth's AED 1.74 billion against its AED 10.1 billion of normalised revenue and the margin is about 17.2% on our arithmetic, below the prior year's 17.7%. Treat that as a guide: PureHealth's normalisation also reverses internal eliminations, and it publishes no normalised EBITDA. The dirham figure can move too.

Burjeel's Q1 2026 MD&A reports Burjeel Medical City EBITDA stable at AED 52 million, or AED 61 million normalised, on revenue of AED 306 million against AED 315 million a year earlier (Burjeel Q1 2026 MD&A), a difference of AED 9 million in one quarter on our arithmetic. Where the markup is smaller than the margin a hospital used to earn buying and reselling the drug, including discounts Circular 14/2025 waived, EBITDA in dirhams falls for good while the percentage can still rise.

05

The break falls on a different date for each provider

Activation was gradual from 15 April 2025, and each drug line carries its own UPP effective date (DoH Circular 27/2025). Burjeel dates the programme's effect on its business to August 2025 and describes a residual impact on reported revenue during January to July 2026 (Burjeel 9M 2026 MD&A).

A three-year trend for an Abu Dhabi provider therefore mixes gross and net years, with the step in a month set facility by facility. A last-twelve-months figure struck after the anniversary is consistent with itself; the history used to show margin trajectory is not.

06

Restate before you apply a multiple

Ask the CFO for revenue and cost of UPP-flagged drugs by month from January 2024, split by Thiqa, Basic, government mandates and Enhanced, and for the date UPP went live at each licensed facility.

Restate the pre-programme periods on the net basis so revenue, inventory consumed and margin compare like for like, and carry the lost drug margin as a run-rate adjustment to EBITDA rather than a one-off. Compare EBITDA in dirhams across periods before comparing percentages, and apply the same restatement to any Abu Dhabi comparable whose margin you borrow.

Ask who owns UPP stock on the shelf and how replenishment runs through inventory and payables, then set any working capital peg on post-programme months. Ask for the signed distributor agreement that Circular 97/2025 makes mandatory (DoH Circular 97/2025). Putting a target and its comparables on one basis before pricing is the work of our business valuation practice.

Before your next meeting

Four questions before a multiple is applied

  1. What were revenue and cost of UPP-flagged drugs, month by month since January 2024, split by Thiqa, Basic, government mandates and Enhanced?
  2. On what date did UPP go live at each of our licensed facilities, and which periods in the information memorandum are reported gross?
  3. What is EBITDA in dirhams for each period once the pre-programme years are restated on the net basis, and how much drug margin has gone for good?
  4. Have the comparable companies' margins been put on the same basis as ours, and does their normalised figure strip more than UPP?

Subscribe

The UAE healthcare regulatory briefing

What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.

One email a fortnight. Unsubscribe from any of them.

Engagement · Limited mandates

Choosing who advises you is itself a strategic decision.

We take a limited number of mandates at any time. If you are working a decision that needs independent counsel, start with a conversation.